ArticleInfection and drug resistance2022
The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis.
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Drivers of drug-resistant tuberculosis treatment initiation delay at three tertiary health facilities in Uganda: A mixed-methods study.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Human biomarker navigator.iMeta · 2026Review
- Diagnostic and treatment delays and associated factors among RR-TB patients under molecular drug susceptibility testing: a retrospective study in Guizhou Province, China.BMC infectious diseases · 2026Article
- Diagnostic Delay Among Pulmonary Tuberculosis Patients Before, During and After COVID-19 Pandemic in Yichang City, China: A Longitudinal Study Based on Tuberculosis Surveillance Data.Journal of epidemiology and global health · 2025Article
- Prevention and control of multidrug-resistance tuberculosis in Ethiopia: Patients' perspectives from the Oromia region.PloS one · 2025Article
- Predictors of treatment delay among drug resistant tuberculosis patients in Uganda.BMC infectious diseases · 2024Article
- Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a review.Annals of medicine · 2024Review
- Prevalence of Drug-Resistant Tuberculosis in HIV-Positive and Diabetic Patients in Sinaloa, Mexico: A Retrospective Cross-Sectional Study.Tropical medicine and infectious disease · 2024Article
- Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.BMC infectious diseases · 2024Article
- Assessing heterogeneity of patient and health system delay among TB in a population with internal migrants in China.Frontiers in public health · 2024Article
- Infectious disease control: from health security strengthening to health systems improvement at global level.Global health research and policy · 2023Article
- Diagnostic biomarkers for active tuberculosis: progress and challenges.EMBO molecular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGeneXpert MTB/RIF testing is a rapid molecular diagnostic test that is performed with an automated cartilage-based machine that makes treatment initiation prompt. This study aimed at evaluating the impact of GeneXpert in the reduction of treatment delay among multidrug-resistant tuberculosis (MDR-TB) patients in Amhara regional state of Ethiopia.
methodsA facility-based retrospective follow-up study was conducted from January to February 2019, and a total of 465 MDR-TB patients were included in the study. Socio-demographic, clinical, and treatment-related characteristics were collected from patient's chart retrospectively using data abstraction sheets. Binary logistic regression model was fitted to identify factors associated with treatment delay; adjusted odds ratio (AOR) with a 95% confidence interval (CI) was computed to assess the strength of association. A propensity score-matched (PSM) analysis was used to assess the impact of the GeneXpert MTB/RIF test on treatment delay through calculation of average treatment effect (ATE).
resultsThe majority, 92.4%, of patients had the pulmonary form of TB, and 46.7% of patients were diagnosed by GeneXpert MTB/RIF. The presence of cavitation (AOR = 0.62, 95% CI: 0.39 0.96), extrapulmonary form of TB (AOR = 0.34, 95% CI: 0.14 0.81), and GeneXpert (AOR = 0.15, 95% CI: 0.10 0.24) were factors associated with treatment delay. The average treatment effect (ATE) of PSM analysis showed that GeneXpert MTB/RIF has significantly reduced treatment delay by 41% compared to matched control groups.
conclusionThis study revealed that GeneXpert test has a strong association with the reduced treatment delays among MDR-TB patients. This underscores that rapid molecular tests could help improve the health system and lead to prompt initiation of MDR-TB treatment. Therefore, expansion and decentralization of GeneXpert tests to peripheral health facilities are highly recommended. In turn, the case detection and control of the disease will be hastened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.